World J Mens Health.  2020 Jan;38(1):132-136. 10.5534/wjmh.180130.

Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review

• Kadomoto S
• Shigehara
• Iwamoto H
• Yaegashi H
• Izumi K
• Kadono Y
• Mizokami A

• KMID: 2465418
• DOI: http://doi.org/10.5534/wjmh.180130

Abstract

We had six cases of patients who were treated with long-term testosterone replacement therapy (TRT) after high dose-rate (HDR) brachytherapy and androgen deprivation therapy for high-risk prostate cancer. All patients were given testosterone enanthate by intramuscular injection every 3 to 4 weeks. Blood biochemistry including prostate specific antigen (PSA) level was evaluated every 3 to 6 months after TRT, and radiological imaging was performed every 12 months. All patients had slight increases in PSA within the normal range and not indicative of biochemical recurrence. A sudden increase in PSA was observed in one patient, but it finally decreased. Aging male symptoms scale and various metabolic factors were improved by TRT in all of cases. Although adverse events included polycythemia in one patient, no patients experienced disease recurrence or progression during TRT. Our results suggest TRT for high risk-patients with HDR brachytherapy for prostate cancer may be beneficial and safe.

Keyword

Hypogonadism; Prostatic neoplasms; Safety; Testosterone

MeSH Terms

Aging
Biochemistry
Brachytherapy*
Humans
Hypogonadism*
Injections, Intramuscular
Male
Polycythemia
Prostate*
Prostate-Specific Antigen
Prostatic Neoplasms*
Recurrence
Reference Values
Testosterone*
Prostate-Specific Antigen
Testosterone

Figure

• 

  Fig. 1 A flow chart to indicate details in each case, including schedule of therapy, the duration of TRT therapy, follow-up time points and evaluation at each time points. nADT: neoadjuvant androgen deprivation therapy, aADT: adjuvant androgen deprivation therapy, HDR: high dose-rate brachytherapy, TRT: testosterone replacement therapy, EBRT: external beam radiation therapy.

Reference

1. Tsujimura A. The relationship between testosterone deficiency and men’s health. World J Mens Health. 2013; 31:126–135. PMID: 24044107.

2. Blaya R, Thomaz LD, Guilhermano F, Paludo Ade O, Rhoden L, Halmenschlager G, et al. Total testosterone levels are correlated to metabolic syndrome components. Aging Male. 2016; 19:85–89. PMID: 26961662.

3. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004; 172:920–922. PMID: 15310998.

4. Khera M, Grober ED, Najari B, Colen JS, Mohamed O, Lamb DJ, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009; 6:1165–1170. PMID: 19207277.

5. Balbontin FG, Moreno SA, Bley E, Chacon R, Silva A, Morgentaler A. Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer. BJU Int. 2014; 114:125–130. PMID: 25101359.

6. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007; 109:536–541. PMID: 17183557.

7. Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, Liu JS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013; 190:639–644. PMID: 23395803.

8. Pastuszak AW, Khanna A, Badhiwala N, Morgentaler A, Hult M, Conners WP, et al. Testosterone therapy after radiation therapy for low, intermediate and high risk prostate cancer. J Urol. 2015; 194:1271–1276. PMID: 26025500.

9. Tsumura H, Satoh T, Ishiyama H, Hirano S, Tabata K, Kurosaka S, et al. Recovery of serum testosterone following neoadjuvant and adjuvant androgen deprivation therapy in men treated with prostate brachytherapy. World J Radiol. 2015; 7:494–500. PMID: 26753064.

10. Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and management of testosterone deficiency: AUA Guideline. J Urol. 2018; 200:423–432. PMID: 29601923.